The present study explores the use of alpha-particle-emitting, bone-seeking agents as candidates for targeted radiotherapy. Actinium and thorium 1,4,7,10 tetraazacyclododecane N,N',N'',N''' 1,4,7,10-tetra(methylene) phosphonic acid (DOTMP) and thorium-diethylene triamine N,N',N'' penta(methylene) phosphonic acid (DTMP) were prepared and their biodistribution evaluated in conventional Balb/C mic...

Intoduction: Therapeutic radiopharmaceuticals are radiolabeled molecules to deliver sufficient doses of ionizing radiation to specific disease sites such as bone metastases, brain and liver tumors and bone marrows malignancies including multiple myeloma. Among some therapeutic radiopharmaceuticals, Ho-1,4,7,10 – tetraazacyclo dodecane–1,4,7,10 tetraethylene phosphonic acid (Ho-DOTMP) is used fo...

The measurement of organ radiation exposure dose is one of the most important steps to be taken initially, for developing a new radiopharmaceutical. In this study, the dosimetric studies of a novel agent for SPECT-imaging of the bone metastasis, 111In1,4,7,10-tetraazacyclododecane-1,4,7,10 tetraethylene phosphonic acid (111In-DOTMP) complex, have been carried out to estimate the dose in human o...

intoduction: therapeutic radiopharmaceuticals are radiolabeled molecules to deliver sufficient doses of ionizing radiation to specific disease sites such as bone metastases, brain and liver tumors and bone marrows malignancies including multiple myeloma. among some therapeutic radiopharmaceuticals, 166ho-1,4,7,10 -tetraazacyclo dodecane-1,4,7,10 tetraethylene phosphonic acid (166ho-dotmp) is us...

  Intoduction: Therapeutic radiopharmaceuticals are radiolabeled molecules to deliver sufficient doses of ionizing radiation to specific disease sites such as bone metastases, brain and liver tumors and bone marrows malignancies including multiple myeloma. Among some therapeutic radiopharmaceuticals, 166Ho-1,4,7,10 -tetraazacyclo dodecane-1,4,7,10 tetraethy...

Skeletal uptake of radiolabeled-1, 4, 7, 10-tetraazacyclododecane-1, 4, 7, 10-tetramethylene phosphoric acid (e.g., 177Lu-DOTMP) complex, is used for bone pain palliation. The moderate energy of β-emitting 177Lu (T½ = 6.7 d, Eβmax = 497keV) has been considered as a potential radionuclide for development of the bone-seeking radiopharmaceutical. Since the specific activity of the radiolabeled car...

A novel 2-D coordination polymer constructed from high nuclearity nanosized Ho48 clusters was synthesised and structurally characterized using single-crystal X-ray analysis. The Ho48 cluster core with a charming waist drum-like structure was templated by CO3(2-) ions, and bridged by Ho-N bonds to get a 2-D coordination polymer.

Designing ideal radiopharmaceuticals for use as bone pain palliatives require the use of a moderate energy β emitter with a stable carrier molecule. Cyclic polyaminophosphonate ligands are known to form complexes with higher thermodynamic stability and kinetic inertness. The present study therefore envisages the use of a few moderate energy β emitters, viz. Lu (T1/2 = 6.71 d, Eβmax= 497 keV), S...

      Bone is the third most common site of metastatic disease. Bone pain is the major source of morbidity associated bone metastasis. Bone-seeking radiopharma- ceuticals have been applied for many years. The ability to simultaneously treat multiple sites of disease with a more probable therapeutic effect in earlier phases of metastatic disease is one of the advantages of radiopharmaceuticals. ...